

In particular, the present invention relates to the following modified kringle 5 peptides: NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH₂ (SEQ ID NO: 17); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂ (SEQ ID NO: 18); Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂ (SEQ ID NO: 19); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂ (SEQ ID NO: 20); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH₂ (SEQ ID: NO 21); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N ϵ -MPA)-NH₂ (SEQ ID NO: 22); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO: 23); (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO: 24); NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N ϵ -MPA)-NH₂ (SEQ ID NO: 25); (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO: 26); (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO: 27); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N ϵ -MPA)-NH₂ (SEQ ID NO: 28); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO: 29); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO: 30); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-(N ϵ -MPA)-NH₂ (SEQ ID NO: 31); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH₂ (SEQ ID NO: 32); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH₂ (SEQ ID NO: 33); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N ϵ -MPA)-NH₂ (SEQ ID NO: 34); (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO: 35); (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO: 36); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(N ϵ -MPA)-NH₂ (SEQ ID NO: 37); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂ (SEQ ID NO: 38); (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂ (SEQ ID NO: 39); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N ϵ -AEEA-MPA)-NH₂ (SEQ ID NO: 40); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N ϵ -AEEA_n-MPA)-NH₂ (SEQ ID NO: 41); and other modified kringle 5 peptides.

Please replace the paragraph beginning at page 40, line 1, with the following rewritten paragraph:

Example 1

Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH₂.3TFA (SEQ ID NO: 42)

Please replace the paragraph beginning at page 40, line 15, with the following rewritten paragraph:

Example 2

Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂.3TFA (SEQ ID NO: 43)

Please replace the paragraph beginning at page 40, line 29, with the following rewritten paragraph:

Example 3

Preparation of Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂.3TFA (SEQ ID NO: 44)

Please replace the paragraph beginning at page 41, line 14, with the following rewritten paragraph:

Example 4

Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂.4TFA (SEQ ID NO: 45)

Please replace the paragraph beginning at page 42, line 2, with the following rewritten paragraph:

Example 5

A 7 Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH₂.2TFA (SEQ ID NO: 46) --

Please replace the paragraph beginning at page 42, line 18, with the following rewritten paragraph:

Example 6

A 8 Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂.2TFA (SEQ ID NO: 47) --

Please replace the paragraph beginning at page 43, line 16, with the following rewritten paragraph:

Example 7

A 9 Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.2TFA (SEQ ID NO: 48) --

Please replace the paragraph beginning at page 44, line 13, with the following rewritten paragraph:

Example 8

A 10 Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.2TFA (SEQ ID NO: 49) --

Please replace the paragraph beginning at page 45, line 7, with the following rewritten paragraph:

Example 9

A¹¹ Preparation of NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂.2TFA (SEQ ID NO: 50) --

Please replace the paragraph beginning at page 46, line 4, with the following rewritten paragraph:

Example 10

A¹² Preparation of (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.2TFA (SEQ ID NO: 51) --

Please replace the paragraph beginning at page 47, line 3, with the following rewritten paragraph:

Example 11

A¹³ Preparation of (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.2TFA (SEQ ID NO: 52) --

Please replace the paragraph beginning at page 48, line 1, with the following rewritten paragraph:

Example 12

A¹⁴ Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂.3TFA (SEQ ID NO: 53) --

Please replace the paragraph beginning at page 49, line 4, with the following rewritten paragraph:

Example 13

A¹⁵ Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.3TFA (SEQ ID NO: 54) --

Please replace the paragraph beginning at page 50, line 7, with the following rewritten paragraph:

Example 14

A¹⁶ Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.3TFA (SEQ ID NO: 55) --

Please replace the paragraph beginning at page 51, line 6, with the following rewritten paragraph:

Example 15

A¹⁷ Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-(Nε-MPA)-NH₂.TFA (SEQ ID NO: 56) --

Please replace the paragraph beginning at page 52, line 4, with the following rewritten paragraph:

Example 16

A¹⁸ Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH₂.TFA (SEQ ID NO: 57) --

Please replace the paragraph beginning at page 53, line 2, with the following rewritten paragraph:

Example 17

A¹⁹ Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH₂.TFA (SEQ ID NO: 58) —

Please replace the paragraph beginning at page 54, line 1, with the following rewritten paragraph:

Example 18

A²⁰ Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂.2TFA (SEQ ID NO: 59) —

Please replace the paragraph beginning at page 54, line 30, with the following rewritten paragraph:

Example 19

A²¹ Preparation of (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.2TFA (SEQ ID NO: 60) —

Please replace the paragraph beginning at page 55, line 26, with the following rewritten paragraph:

Example 20

A²² Preparation of (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.2TFA (SEQ ID NO: 61) —

Please replace the paragraph beginning at page 56, line 20, with the following rewritten paragraph:

Example 21

A²³ Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(Nε-MPA)-NH₂.2TFA (SEQ ID NO: 62) --

Please replace the paragraph beginning at page 57; line 17, with the following rewritten paragraph:

Example 22

A²⁴ Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂.2TFA (SEQ ID NO: 63) --

Please replace the paragraph beginning at page 58, line 13, with the following rewritten paragraph:

Example 23

A²⁵ Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂.2TFA (SEQ ID NO: 64) --

Please replace the paragraph beginning at page 59, line 7, with the following rewritten paragraph:

Example 24

A²⁶ Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA-MPA)-NH₂.2TFA (SEQ ID NO: 65) --